SCHEMBL169443

SCHEMBL169443

CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COP(=O)(O)O

nearest known ligand 0.77

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FNTA P49354 15/20 0.77
FNTB P49356 13/20 0.77
PGGT1B P53609 6/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29609148 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL30508947 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL1379697 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL25386448 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL812431 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL23674223 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL18042467 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL1379703 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL2506806 1.00 FNTA (0.77) FNTAFNTBPGGT1B
SCHEMBL29420213 1.00 FNTA (0.77) FNTAFNTBPGGT1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3587427-B1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO LTD (KR) 2026-04-29 EP claimed
EP-3185331-B1 ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO LTD (KR) 2024-11-27 EP claimed
EP-3816262-B1 QUANTUM DOT-CONTAINING COMPLEX, AND LIGHT-EMITTING DEVICE, OPTICAL MEMBER, AND DEVICE, EACH INCLUDING THE SAME SAMSUNG DISPLAY CO LTD (KR) 2022-09-21 EP claimed
EP-3737385-B1 GLYCOSYLTRANSFERASE INHIBITORS CALIFORNIA INST OF TECHN (US) 2026-04-15 EP disclosed
EP-3655029-B1 IMMUNOGENIC COMPOSITION GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2026-03-18 EP disclosed
US-12570684-B2 DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2026-03-10 US disclosed
US-20250381257-A1 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-12-18 US disclosed
EP-4619030-A2 MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF Janssen Pharmaceuticals, Inc. (US) 2025-09-24 EP disclosed
US-12398380-B2 Methods of host cell modification GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-08-26 US disclosed
US-20250222088-A1 MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF Janssen Pharmaceuticals, Inc. 2025-07-10 US disclosed
US-20250222093-A1 METHODS OF PRODUCING BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF Janssen Pharmaceuticals, Inc. 2025-07-10 US disclosed
WO-2001012142-A1 METHODS FOR ASSAYING TRANSGLYCOSYLASE REACTIONS, AND FOR IDENTIFYING INHIBITORS THEREOF IRL, INC. (US) 2001-02-22 WO disclosed
EP-1076719-A1 A SCINTILLATION PROXIMITY ASSAY FOR THE DETECTION OF PEPTIDOGLYCAN SYNTHESIS AstraZeneca AB (SE) 2001-02-21 EP disclosed
WO-2000070060-A1 PRODUCTION OF COMPLEX CARBOHYDRATES UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2000-11-23 WO disclosed
EP-1005537-A1 NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF THE UNIVERSITY OF SYDNEY (AU) 2000-06-07 EP disclosed
WO-1999062459-A9 AGENTS AND METHODS FOR PROTECTION, TREATMENT AND REPAIR OF CONNECTIVE TISSUE NUTRAMAX LAB INC (US) 2000-04-27 WO disclosed
WO-1999062459-A2 AGENTS AND METHODS FOR PROTECTION, TREATMENT AND REPAIR OF CONNECTIVE TISSUE NUTRAMAX LABORATORIES, INC. (US) 1999-12-09 WO disclosed
WO-1999061458-A1 ANTIGENS AND THEIR DETECTION THE UNIVERSITY OF SYDNEY (AU) 1999-12-02 WO disclosed
WO-1999060155-A1 A SCINTILLATION PROXIMITY ASSAY FOR THE DETECTION OF PEPTIDOGLYCAN SYNTHESIS ASTRAZENECA AB (SE) 1999-11-25 WO disclosed
WO-1998050531-A1 NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF THE UNIVERSITY OF SYDNEY (AU) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250222093-A1 METHODS OF PRODUCING BIOCONJUGATES OF E. COLI O-ANTIGEN POLYSACCHARIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF OSTC, PGLS, ENGASE FNTA 467/4885FNTB 203/4885PGGT1B 308/4885
US-20250222088-A1 MULTIVALENT VACCINE COMPOSITIONS AND USES THEREOF MLEC, ENGASE, CD63 FNTA 524/4885FNTB 572/4885PGGT1B 753/4885
US-12570684-B2 DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors DPAGT1, MAGT1, DAD1 FNTA 273/4885FNTB 426/4885PGGT1B 583/4885
US-20250381257-A1 VACCINE WIZ, STT3B, VAC14 FNTA 296/4885FNTB 33/4885PGGT1B 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.